3 hours Monopar Therapeutics Skyrockets 400% on Licensing DealMarketBeat
Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.
XMonopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.
X